News for X4 Pharmaceuticals, Inc. (XFOR)

X4 Pharmaceuticals (XFOR) unveiled promising outcomes from its completed Phase 2 clinical trial of mavorixafor during the European Hematology Association's 30th

X4 Pharmaceuticals (XFOR) has secured Fast Track designation from the U.S. Food and Drug Administration (FDA) for its oral medication, mavorixafor, aimed at tre

X4 Pharmaceuticals (XFOR) grants stock options as inducement awards under the 2019 Inducement Plan. A total of 5,545 shares are available with an exerci

Operator: Greetings, and welcome to the X4 Pharmaceuticals First Quarter 2025 Financial and Operating Results Conference Call. At this time, all participants are in a listen-only mode.

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ETCompany ParticipantsDan Ferry - Investor Relations-LifeSci...

Key Takeaways: X4 Pharmaceuticals (XFOR) posted a GAAP EPS of $0.04 with a revenue of $28.8 million in Q1. The company's robust position includes $87.7 m

4WARD Phase 3 chronic neutropenia trial in full swing; full enrollment on track for 3Q or 4Q 2025 and top-line data in 2H 2026 Additional analyses of mavorixaf

Revenue: Achieved $28.8 million in net revenue for Q1 2025, significantly surpassing the estimated $2.00 million.Earnings Per Share (EPS): Reported EPS of $0.0

X4 Pharmaceuticals (XFOR) reports impressive Q1 results with GAAP EPS of $0.04, revenue of $28.8M, and a strong $87.7M cash position.

We recently published a list of Why These 15 Healthcare Stocks Are Surging in 2025. In this article, we are going to take a look at where X4 Pharmaceuticals, Inc.

We recently published a list of Why These 15 Healthcare Stocks Are Surging in 2025. In this article, we are going to take a look at where X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) stands against other healthcare stocks that are surging in 2025. After lagging behind the broader market in 2024, many healthcare stocks are making a […]

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a...

BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals ( XFOR), a company driven to improve the lives of people with rare diseases of the immune system

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2024 Earnings Conference Call March 25, 2025 8:30 AM ETCompany ParticipantsDaniel Ferry - IR, LifeSci...

Revenue: Reported net product revenue of $1.4 million for Q4 2024, surpassing the estimated revenue of $1.04 million.Earnings Per Share (EPS): Recorded a net l

Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line data anticipated i

**media[575631]**

X4 Pharmaceuticals (XFOR) Q4 earnings release on Mar 25: EPS estimate at -$0.16 & revenue at $1.06M.

X4 Pharmaceuticals Inc (XFOR) is set to release its Q4 2024 earnings on Mar 25, 2025. The consensus estimate for Q4 2024 revenue is $1.04 million, and the earni